Profile data is unavailable for this security.
About the company
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
- Revenue in CHF (TTM)-1.60m
- Net income in CHF-55.53m
- Incorporated2002
- Employees39.00
- LocationSanthera Pharmaceuticals Holding AGHohenrainstrasse 24PRATTELN 4133SwitzerlandCHE
- Phone+41 619068950
- Fax+41 619068951
- Websitehttps://www.santhera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Addex Therapeutics Ltd | 2.47m | -18.38m | 14.62m | 28.00 | -- | 0.6551 | -- | 5.91 | -0.5203 | -0.5203 | 0.0706 | 0.3419 | 0.1111 | -- | 27.75 | 88,386.79 | -82.51 | -43.18 | -102.20 | -50.38 | -- | -- | -742.76 | -279.82 | -- | -64.69 | 0.0309 | -- | -18.71 | 51.13 | -18.19 | -- | 22.97 | -- |
| Newron Pharmaceuticals SpA | 5.61m | -14.51m | 25.21m | 25.00 | -- | 8.34 | -- | 4.49 | -0.813 | -0.813 | 0.3144 | 0.1695 | 0.1133 | -- | 3.64 | 224,401.20 | -29.31 | -25.64 | -32.70 | -28.17 | 97.97 | 86.47 | -258.61 | -216.08 | -- | -4.64 | 0.9327 | -- | 9.59 | 4.00 | 29.04 | -- | -22.60 | -- |
| Spexis AG | 0.00 | -11.86m | 39.28m | -- | -- | 1.29 | -- | -- | -0.8155 | -0.8155 | 0.00 | 0.6333 | 0.00 | -- | -- | -- | -24.54 | -- | -34.72 | -- | -- | -- | -- | -- | -- | -0.5579 | 0.1832 | -- | -100.00 | -- | 73.61 | -- | -- | -- |
| Santhera Pharmaceuticals Holding AG | -1.60m | -55.53m | 62.67m | 39.00 | -- | 31.74 | -- | -- | -1.68 | -1.68 | -0.0467 | 0.0268 | -0.0177 | 8.29 | -- | -40,897.44 | -61.76 | -48.15 | -94.15 | -60.86 | -- | 80.16 | -- | -172.87 | 0.7386 | -7.27 | 0.97 | -- | -110.63 | -- | 17.93 | -- | -47.47 | -- |
| Wockhardt Bio AG | 316.21m | -42.86m | 77.94m | -- | -- | 0.2617 | -- | 0.2465 | -0.7681 | -0.7681 | 6.09 | 5.73 | 0.4792 | 1.80 | 2.50 | -- | -6.50 | -0.7439 | -8.19 | -1.25 | 51.44 | 52.97 | -13.55 | -1.62 | 3.90 | -3.45 | 0.5092 | -- | 12.15 | -2.14 | -107.96 | -- | -8.03 | -- |
| Xlife Sciences AG | 806.06k | 53.42m | 131.12m | 19.00 | 3.93 | 0.5964 | 2.46 | 162.66 | 6.33 | 6.33 | 0.1307 | 41.75 | 0.0024 | -- | 3.19 | 42,424.21 | 16.00 | -- | 19.29 | -- | 44.55 | -- | 6,609.35 | -- | -- | -0.2664 | 0.1659 | -- | 103.14 | -- | 148.91 | -- | -- | -- |
| RELIEF THERAPEUTICS Holding SA | 3.32m | -34.71m | 144.72m | 55.00 | -- | 0.7478 | -- | 43.58 | -0.0096 | -0.0096 | 0.0009 | 0.0441 | 0.0202 | -- | -- | 60,381.82 | -21.05 | -17.42 | -22.89 | -18.92 | 77.42 | -- | -1,045.02 | -1,372.00 | 2.77 | -389.09 | 0.023 | -- | -- | 194.47 | -343.34 | -- | 316.02 | -- |
| Molecular Partners AG | -100.00bn | -100.00bn | 203.47m | 163.00 | -- | 0.77 | -- | -- | -- | -- | -- | 8.18 | -- | -- | -- | -- | -- | -29.24 | -- | -37.44 | -- | 95.94 | -- | -322.54 | -- | -- | 0.0213 | -- | 4.39 | -15.79 | -1.63 | -- | 3.57 | -- |
Data as of Aug 09 2022. Currency figures normalised to Santhera Pharmaceuticals Holding AG's reporting currency: Swiss Franc CHF
2.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Asset Management (Schweiz) AGas of 29 Jul 2022 | 542.83k | 0.74% |
| Armistice Capital LLCas of 27 Sep 2021 | 494.15k | 0.67% |
| UBS Asset Management Switzerland AGas of 05 Jul 2022 | 286.25k | 0.39% |
| TOBAM SASas of 31 Dec 2020 | 172.46k | 0.23% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020 | 139.48k | 0.19% |
| Pictet Asset Management SAas of 30 Apr 2022 | 74.61k | 0.10% |
| BlackRock Asset Management Schweiz AGas of 07 Jul 2022 | 47.72k | 0.07% |
| CATAM Asset Management AGas of 30 Jun 2022 | 30.00k | 0.04% |
| Lombard Odier Asset Management (Switzerland) SAas of 31 May 2022 | 6.74k | 0.01% |
| DWS CH AGas of 30 Nov 2020 | 4.00k | 0.01% |
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
